Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis(®) (Ranibizumab) Biosimilar

INTRODUCTION: SB11 was recently approved as a ranibizumab biosimilar by the US Food and Drug Administration (FDA) and the European Commission (EC) as a therapy for retinal vascular disorders under the brand name Byooviz™. This study was performed to assess the analytical similarity between SB11 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eunji, Han, Jihyeon, Chae, Yunjung, Park, Hyerim, Kim, Saerom, Kim, Seokkyun, Lee, Jungmin, Kim, Beom Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927571/
https://www.ncbi.nlm.nih.gov/pubmed/35084693
http://dx.doi.org/10.1007/s40123-022-00453-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927571/
https://www.ncbi.nlm.nih.gov/pubmed/35084693
http://dx.doi.org/10.1007/s40123-022-00453-7

Ejemplares similares